Bafna Pharmaceuticals (NSE:BAFNAPH) Other Current Liabilities: ₹63 Mil (As of Mar. 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
66 GF Score
Price ₹207.89
GF Value ₹90.81
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Other Current Liabilities?

Bafna Pharmaceuticals NSE:BAFNAPH -2.00% 66 Other Current Liabilities is ₹63 Mil as of Mar. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 66/100 and a GF Value™ of ₹90.81 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Bafna Pharmaceuticals's other current liabilities for the quarter that ended in Mar. 2026 was ₹63 Mil.

Bafna Pharmaceuticals's quarterly other current liabilities declined from Sep. 2025 (₹87 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹63 Mil).

Bafna Pharmaceuticals's annual other current liabilities increased from Mar. 2024 (₹15 Mil) to Mar. 2025 (₹24 Mil) and increased from Mar. 2025 (₹24 Mil) to Mar. 2026 (₹63 Mil).

Bafna Pharmaceuticals Other Current Liabilities Related Terms

Bafna Pharmaceuticals Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Other Current Liabilities Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.26 13.94 15.26 23.89 62.53

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.89 0.00 87.19 0.00 62.53
NSE:BAFNAPH
66GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹63 Mil mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Other Current Liabilities of ₹63 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bafna Pharmaceuticals.
Is Bafna Pharmaceuticals' Other Current Liabilities too high?
Bafna Pharmaceuticals' current Other Current Liabilities is ₹63 Mil. Overall, Bafna Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Other Current Liabilities compare to ZTS and UTHR?
Bafna Pharmaceuticals' Other Current Liabilities of ₹63 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bafna Pharmaceuticals. Bafna Pharmaceuticals's current Other Current Liabilities is ₹63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.81, compared to a current price of ₹207.89 — trading 128.9% above its estimated fair value. The current Other Current Liabilities is ₹63 Mil. Bafna Pharmaceuticals' overall GF Score™ is 66/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Other Current Liabilities is ₹63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹207.89 is trading 128.9% above its estimated GF Value™ of ₹90.81. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Other Current Liabilities: ₹63 Mil
  • GF Value™: ₹90.81 vs. price of ₹207.89 (128.9% above fair value)
  • GF Score™: 66/100 with 9 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
66GF Score

Get the complete analysis for NSE:BAFNAPH

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹207.89
Price
₹90.81
GF Value